Wave Life Sciences Adds to Gains After Analysts Raise Price Targets

Dow Jones12-10

By Josh Beckerman

Wave Life Sciences shares, which skyrocketed Monday on favorable interim Phase 1 data for weight loss drug WVE-007, gained on Tuesday after analysts raised price targets.

Shares rose 147% to $18.52 on Monday, and were recently up 14% to $21.18. They touched a 52-week high of $21.73.

Wells Fargo raised its price target to $29 from $16, while RBC Capital raised its target to $27 from $9. Citigroup, Canaccord Genuity, Clear Street and Cantor Fitzgerald also increased their price targets.

Wave Life Sciences said that following a single subcutaneous 240-mg dose, WVE-007 improved body composition at three months compared to baseline, with a 9.4% reduction in visceral fat.

Write to Josh Beckerman at josh.beckerman@wsj.com

(END) Dow Jones Newswires

December 09, 2025 15:15 ET (20:15 GMT)

At the request of the copyright holder, you need to log in to view this content

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2590291443?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-12-10 04:15","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2590291443","market":"us","top_or_hot":-1,"title":"Wave Life Sciences Adds to Gains After Analysts Raise Price Targets","media":"Dow Jones","content":"<font class=\"NormalMinus1\" face=\"Arial\">\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  By Josh Beckerman \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  <a href=\"https://laohu8.com/S/WVE\">Wave Life</a> Sciences shares, which skyrocketed Monday on favorable interim Phase 1 data for weight loss drug WVE-007, gained on Tuesday after analysts raised price targets. \n</p>\n<p>\n  Shares rose 147% to $18.52 on Monday, and were recently up 14% to $21.18. They touched a 52-week high of $21.73. \n</p>\n<p>\n  <a href=\"https://laohu8.com/S/EOD\">Wells Fargo</a> raised its price target to $29 from $16, while RBC Capital raised its target to $27 from $9. Citigroup, <a href=\"https://laohu8.com/S/CCORF\">Canaccord Genuity</a>, Clear Street and Cantor Fitzgerald also increased their price targets. \n</p>\n<p>\n  Wave Life Sciences said that following a single subcutaneous 240-mg dose, WVE-007 improved body composition at three months compared to baseline, with a 9.4% reduction in visceral fat. \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  Write to Josh Beckerman at josh.beckerman@wsj.com \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  December 09, 2025 15:15 ET (20:15 GMT)\n</p>\n<p>\n  Copyright (c) 2025 Dow Jones &amp; Company, Inc.\n</p>\n</font>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Wave Life Sciences Adds to Gains After Analysts Raise Price Targets</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nWave Life Sciences Adds to Gains After Analysts Raise Price Targets\n</h2>\n\n<h4 class=\"meta\">\n\n\n<div class=\"head\" \">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Dow Jones </p>\n<p class=\"h-time\">2025-12-10 04:15</p>\n</div>\n\n</div>\n\n\n</h4>\n\n</header>\n<article>\n<font class=\"NormalMinus1\" face=\"Arial\">\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  By Josh Beckerman \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  <a href=\"https://laohu8.com/S/WVE\">Wave Life</a> Sciences shares, which skyrocketed Monday on favorable interim Phase 1 data for weight loss drug WVE-007, gained on Tuesday after analysts raised price targets. \n</p>\n<p>\n  Shares rose 147% to $18.52 on Monday, and were recently up 14% to $21.18. They touched a 52-week high of $21.73. \n</p>\n<p>\n  <a href=\"https://laohu8.com/S/EOD\">Wells Fargo</a> raised its price target to $29 from $16, while RBC Capital raised its target to $27 from $9. Citigroup, <a href=\"https://laohu8.com/S/CCORF\">Canaccord Genuity</a>, Clear Street and Cantor Fitzgerald also increased their price targets. \n</p>\n<p>\n  Wave Life Sciences said that following a single subcutaneous 240-mg dose, WVE-007 improved body composition at three months compared to baseline, with a 9.4% reduction in visceral fat. \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  Write to Josh Beckerman at josh.beckerman@wsj.com \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  December 09, 2025 15:15 ET (20:15 GMT)\n</p>\n<p>\n  Copyright (c) 2025 Dow Jones &amp; Company, Inc.\n</p>\n</font>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4007","symbol_name":"制药","start_time":0,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","article_id":"2590291443","we_media_id":"106","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2590291443","pubTimestamp":1765311300,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Dow Jones","introduction":"Dow Jones publishes the world’s most trusted business news and financial information in a variety of media.","home_visible":0,"id":"106","head_image":"https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99"},"summary":"Wave Life Sciences shares, which skyrocketed Monday on favorable interim Phase 1 data for weight loss drug WVE-007, gained on Tuesday after analysts raised price targets.Shares rose 147% to $18.52 on Monday, and were recently up 14% to $21.18. They touched a 52-week high of $21.73.Wells Fargo raised its price target to $29 from $16, while RBC Capital raised its target to $27 from $9. Citigroup, Canaccord Genuity, Clear Street and Cantor Fitzgerald also increased their price targets.Wave Life Sciences said that following a single subcutaneous 240-mg dose, WVE-007 improved body composition at three months compared to baseline, with a 9.4% reduction in visceral fat.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4007":"制药","WVE":"Wave Life Sciences Pte. Ltd"},"translate_title":"分析师上调目标价后，Wave Life Sciences股价上涨","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"WVE":0.9},"content_text":"By Josh Beckerman \n\n\n \n\n\nWave Life Sciences shares, which skyrocketed Monday on favorable interim Phase 1 data for weight loss drug WVE-007, gained on Tuesday after analysts raised price targets. \n\n\n  Shares rose 147% to $18.52 on Monday, and were recently up 14% to $21.18. They touched a 52-week high of $21.73. \n\n\nWells Fargo raised its price target to $29 from $16, while RBC Capital raised its target to $27 from $9. Citigroup, Canaccord Genuity, Clear Street and Cantor Fitzgerald also increased their price targets. \n\n\n  Wave Life Sciences said that following a single subcutaneous 240-mg dose, WVE-007 improved body composition at three months compared to baseline, with a 9.4% reduction in visceral fat. \n\n\n \n\n\n  Write to Josh Beckerman at josh.beckerman@wsj.com \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  December 09, 2025 15:15 ET (20:15 GMT)\n\n\n  Copyright (c) 2025 Dow Jones & Company, Inc.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":true,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.35.11","shortVersion":"4.35.11","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2590291443","isCrawlerRequest":true}